Compare CBRL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBRL | CGEM |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.2M | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | CBRL | CGEM |
|---|---|---|
| Price | $26.20 | $9.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $35.25 | $28.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.6M |
| Earning Date | 12-09-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $3,435,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.95 | N/A |
| P/E Ratio | $34.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.25 | $5.68 |
| 52 Week High | $71.93 | $13.33 |
| Indicator | CBRL | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 45.54 |
| Support Level | $25.82 | $9.48 |
| Resistance Level | $30.20 | $13.10 |
| Average True Range (ATR) | 1.43 | 0.95 |
| MACD | 0.22 | -0.34 |
| Stochastic Oscillator | 19.09 | 5.25 |
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.